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Effective population-based mammography screening should impact breast cancer (BC) incidence, age and stage-specific incidence
and BC mortality. We aim to investigate such effects in a time period of 10 years after implementation of the German
mammography screening program. Data on 323,719 breast cancer patients from 2003 to 2014 for defined regions covering a
population of 30 million inhabitants and official mortality data from 1998 to 2016 for almost the whole of Germany were used. We
compared incidence and mortality rates for the prescreening time period (2003/2004) and the latest available data (2013/2014 and
2015/2016, respectively) and performed trend analyses using joinpoint regression models. In the screening exposed age groups
(50–59 and 60–69 years), BC incidence showed a typical prevalence peak with the introduction of the mammography screening,
mainly driven by an increase of early-stage BC. For Stage III and IV BC incidence in 2013/2014 was 24.2 and 23.0% (age group
50–59 years) and 28.3 and 24.2% (age group 60–69 years) lower than in the prescreening period. From 2003/2004 to
2015/2016 BC mortality decreased by 25.8 and 21.2%, respectively. As corresponding trends in nonexposed age groups were
distinctly unfavorable, the reduction of late-stage BC incidence and BC mortality in the screening exposed age groups in Germany is
most likely to be attributed to the introduction of the national mammography screening program. These positive effects are bought
at the cost of a moderate occurrence of overdiagnosis, especially by a sharp increase of in situ cancers.
Introduction
Breast cancer (BC) is the most common cancer and the most
common cancer-related cause of death in women in Germany.
In 2018, about 72,000 incident cases were expected1 and about
19,000 women died from BC in 2016.2 To reduce the burden
of BC in Germany a public debate about the implementation
of an organized mammography screening started in the 1990s.
Initial pilot projects were implemented in 2001. In 2002, the
German parliament decided to introduce an organized,
population-based national breast cancer screening program
for women aged 50–69 years. In 2005, the rollout of the
screening program, which is strictly following the European
guidelines on breast cancer screening (EUREF),3 started and
was completely implemented nation-wide until 2009. Key fea-
tures of the program are: 94 mammography units (each cover-
ing a population of about 500,000 to 1 million), a centralized
population-based invitation system, invitation every 2 years
with a proposal of time and place for the examination, inde-
pendent double reading of mammograms, high level quality
assurance by reference centers and a national evaluation unit
with yearly benchmarking. Today almost 100% of German
women aged 50 to 69 years are invited to the mammography
screening every 2 years, and participation rate is about 50%
since the year 2009.4 The program is in full compliance with
relevant quality process indicators of the EUREF guideline.
Until today, there is only a little information on population-
based outcome measures of the German mammography screen-
ing like the frequency of advanced cancers or BC mortality.
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There is an ongoing project with the aim to compare BC mortal-
ity in screening attenders and nonattenders in Germany, but
results of our study are not expected before the end of 2020.
Effects of the screening should also be observable in the popula-
tion context. When an effective mammography screening pro-
gram is introduced, there are several epidemiological effects to
be expected in the screened population. First, BC incidence
should show an initial short-term increase (prevalence peak)
with the following decline. Second, after several years the inci-
dence of late-stage BC should decline below the level of the pres-
creening period. Third, BC mortality should decrease in the long
term. In broad terms, these effects should be observed mainly in
the screened age group while they should not or to a lesser
extent occur in the not screened age groups. The aim of our
study is to investigate trends in total and stage-specific female
BC incidence and BC mortality in screened and not screened
age groups before and after the introduction of the German
mammography screening program.
Methods
Data and data sources
The analysis of incidence is based on anonymized individual
data of female patients with first (incident) registered ductal
carcinoma in situ (DCIS, ICD10: D05.1, representing about
95% of all in situ BCs) or invasive BC diagnosis (ICD-10:
C50). Data on BC cases were retrieved from the German Cen-
tre of Cancer Registry Data at the Robert Koch-Institute,
Berlin, which collects all cancer data from the population-
based cancer registries of the 16 German federal states. We
excluded cases only registered on the basis of a death certifi-
cate (DCO cases) due to the lack of information on tumor
stage and time of diagnosis at initial diagnosis (n = 18.601,
5.9% of all invasive BCs). Population data, aggregated by
5 years age groups, was extracted from official population sta-
tistics.2 Additionally, we retrieved official mortality data for
BC (ICD10: C50, cases by 5 years age groups).2
As only anonymized or aggregated data were used, no ethi-
cal approval of an ethical review board was required.
Study period and region
The study period for the incidence analyses was set from the
year 2003 to the year 2014. The study period was selected by
balancing a sufficiently long time-period before the implemen-
tation of the mammography screening program with the avail-
ability of population-based cancer registry data for a huge,
representative population. The available data enables us to esti-
mate a prescreening incidence for the years 2003/2004, as the
first screening units started in late 2005. Most recent data were
available for the year 2014, providing a 10-year period after first
and a 5-year period after full screening implementation.
We included data from 10 out of 16 federal states into the
analysis of incidence. For four federal states (Baden–
Wurttemberg, Berlin, Hesse and Saxony–Anhalt) registration
was not present or not complete for the whole study period,
for North Rhine-Westphalia only data from the district of
Muenster was available. Two further federal states (Bremen
and Bavaria) had to be excluded from the analysis due to local
statewide screening activities prior to the introduction of the
national screening program. Overall, the study region covers a
population of 30.8 million inhabitants, representing about
37.7% of the German population.
Data on BC mortality was available all over Germany from
1998 to 2016. Bavaria and Bremen were excluded again for
the reason explained above, giving a mean population of 68.8
million inhabitants for mortality analyses.
Information on tumor stage
Stage was defined by cancer registries according to the TNM
classification system of the Union for International Cancer
Control (UICC) using T- (tumor size), N- (the presence of
affected lymph node) and M- (the presence of metastasis) cat-
egory. These categories allowed generating UICC stage with
following categories (statement simplified, for detailed
descriptions, see UICC5): Stage 0: in situ BC, Stage I: tumor
≤2 cm, no lymph nodes affected, Stage II: tumor larger than
2 cm but smaller than 5 cm and no lymph nodes affected or
tumor smaller than 2 cm and 1–3 lymph nodes affected, Stage
III: lymph nodes positive or any size tumor with direct exten-
sion, Stage IV: distant metastases present.
Because missing information on stage could substantially
bias incidence trends, missing information on stage was
treated by multiple imputation.6,7 In total, 19.2% of all inva-
sive BC cases had missing data for UICC stage, which was
imputed three times by predictive mean matching depending
on individual clinical and patient characteristics.
Statistical analysis
For total incidence and mortality, we calculated age-
standardized rates using the European standard population
(1976). Additionally, we calculated age-specific rates by age
What’s new?
Effective mammography screening should have an impact on breast cancer (BC) incidence and mortality. Until today, however,
there is little information available on the population-based outcomes of the national breast cancer screening program in
Germany. Here, the authors present age-specific population-based data before and after implementation of the program.
Compared to non-exposed age groups, screening-eligible women showed more favorable trends regarding the incidence of
late-stage BC and BC mortality. A persistent excess of BC incidence, mainly driven by an increase of in situ cancers, indicated a
moderate amount of overdiagnosis.
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group and UICC stage (for incidence). Six age groups were
considered: 50–59 and 60–69 years as screening exposed age
groups and 20–39 years, 40–49 years, 70–79 years and 80+
years as nonexposed age groups. The age group younger than
20 years was excluded from age-specific analyses due to small
case numbers (n = 18, 0.005%, during the total study period).
First, we calculated the percentage change of the incidence by
dividing mean rates of the most recent 2 years with mammog-
raphy screening (2013/2014) by mean rates of the two first
years (2003/2004), representing baseline incidence, before
introduction of the mammography screening. For the analysis
of mortality, we compared 2003/2004 to 2015/2016. Second,
time trends were calculated by using joinpoint regression
models (SEER joinpoint software 4.7.0.0). Joinpoint regression
fits piecewise log-linear regression lines to the data and pro-
vides estimates of annual percentage changes (APC). A
maximum of two joinpoints was allowed for estimation.
Weighted Bayesian Information Criterion (BIC) was used for
model selection. Then, 95% confidence limits were provided
for the estimations of change and the APCs.
Data availability
Data for BC incidence is available from the German Centre of
Cancer Registry Data at the Robert Koch-Institute, Berlin
(Scientific Use File, www.krebsdaten.de). Mortality data for
BC and population data are available from the Information
System of the Federal Health Monitoring (www.gbe-bund.de).
Results
Incidence
A total of 323,719 BC cases (24,687 DCIS (7.6%) and 299,032
(92.4%) invasive BC) were recorded from 2003 to 2014
(Table 1). Age-standardized incidence trends for DCIS, invasive
BC and total are shown in Figure 1a. Incidence for invasive BC
was 103/100,000 before the introduction of mammography
screening (2003/2004), 125/100,000 in the years of full imple-
mentation (2008/2009) and 114/100,000 in 2013/2014 (most
recent data), giving a 21.6% increase for the typical prevalence
peak and a 10.6% increase for the most recent period compared
to prescreening incidence. The incidence of DCIS showed an
increase of 121.7% from the prescreening period to the peak in
2008/2009 and remained at this level until 2013/2014. Total inci-
dence of BC (DCIS and invasive) increased from 112/100,000 to
134/100,000. Assessing BC incidence within the age groups
(Fig. 1b), incidence for invasive BC in the screening age groups
was higher in 2013/2014 than before the screening implementa-
tion (50–59 years: +7.4%, 60–69 years: +10.4%). Including DCIS
the increase was 16.9 and 18.8%, respectively. In the non-
screening age groups, a substantial incidence increase was also
observed (invasive BC: 20–39 years: +7.5%, 40–49 years: +18.9%,
70–79 years: +10.1%, 80+ years: +9.2%, total incidence including
Table 1. Included federal states of Germany for the analysis of
incidence, their population (mean 2003–2014) and number of
registered DCIS and invasive BC cases (2003–2014), representing
37.7% of the German population
Federal state Population DCIS Invasive BC Total
Brandenburg 2.51 1,890 22,186 24,076
Hamburg 1.75 1,296 17,865 19,161
Lower Saxony 7.91 6,823 80,504 87,327
Mecklenburg-Western
Pomerania
1.66 1,187 14,174 15,361
North Rhine-Westphalia1 2.60 2,422 26,101 28,523
Rhineland-Palatinate 4.03 2,996 38,475 41,471
Saarland 1.03 581 10,578 11,159
Saxony 4.18 3,050 38,003 41,053
Schleswig-Holstein 2.82 2,892 31,578 34,470
Thuringia 2.27 1,550 19,568 21,118
Total 30.76 24,687 299,032 323,719
1data available only for the district of Muenster.
(a) (b) (c)
Figure 1. Breast cancer incidence rates per 100,000 women for (a) all age groups (age-standardized), (b) by age (only invasive BC) and (c) by
UICC stage (only invasive BC). Vertical dotted line: year of implementation of mammography screening (2005).
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DCIS: 20–39 years: +10.4%, 40–49 years: +19.7%, 70–79 years:
+11.6%, 80+ years: +9.6%). The relative increase in incidence in
age group 40–49 years even exceeded the increase in the screen-
ing age groups, but the typical prevalence peak is only visible in
the latter. With the implementation of mammography screening,
the incidence for stage I and stage II increased until 2008/2009,
followed by a decline, but remained higher than the incidence of
the prescreening time period (Fig. 1c). Stage III and IV BC inci-
dence was 14.8 and 16.5% lower in 2013/2014 compared to the
prescreening values.
Figures 2a–2f displays the stage-specific incidence trends
by age groups, Table 2 summarizes the results of joinpoint
analyses and the comparison of prescreening and most
recent BC incidence for the selected age groups. In the two
youngest age groups (20–39 and 40–49 years, representing
20% of all BCs, Figs. 2a and 2b) no significant trend regard-
ing advanced stage incidence can be observed. However, for
age group 40–49 years DCIS, Stage I and II BC incidence
showed statistically significant increases by 31.3, 17.7 and
32.4%, respectively. For the screening age groups (Figs. 2c
and 2d), comprising 50% of all BC cases, a significant
increase of early-stage BC incidence could be observed. The
most recent incidence is 156.6%/164.1% higher for DCIS
and 31.3%/45.1% for stage I BC compared to prescreening.
The incidence of stage II BC showed little change in the
screening age groups when comparing data from 2013/2014
(a) (b) (c)
(d) (e) (f)
Figure 2. Trends in breast cancer incidence by age group (a–f ) and UICC stage in German regions, y-axis: age-specific rates/100,000 women
on a logarithmic scale, dots: observed rates, lines: modeled rates by joinpoint regression, vertical dotted line: year of implementation of
mammography screening (2005).
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Table 2. Breast cancer incidence (rate/100,000) by age group (years) and stage (UICC): comparison of 2003/2004 (before introduction of
mammography screening (Mx) in 2005) with 2013/2014 (after introduction, most recent years) and results of trend analyses (joinpoint: year of













difference (%) Joinpoint Trend APC (%)
20–39 DCIS 1.1 2.0 0.9 [0.5; 1.3] 76.8 [41.5; 112.0] – 2003–2014: 5.1 [2.2; 8.1]
I 9.1 8.7 −0.4 [−1.4; 0.5] −4.7 [−15.2; 5.9] – 2003–2014: −0.8 [−1.3; −0.2]
II 11.3 13.6 2.3 [1.2; 3.4] 20.3 [10.2; 30.3] 2006 2003–2006: −0.5 [−5.2; 4.5]
2006–2014: 2.4 [1.6; 3.2]
III 3.9 4.2 0.3 [−0.4; 0.9] 6.5 [−10.0; 23.1] 2005
2008
2003–2005: 17.9 [−21.8; 77.7]
2005–2008: −7.8 [−32.3; 25.7]
2008–2014: 0.4 [−2.8; 3.7]
IV 1.7 1.5 −0.2 [−0.6; 0.2] −10.2 [−34.5; 14.1] – 2003–2014: −0.5 [−1.5; 0.5]
40–49 DCIS 9.9 12.9 3.1 [1.7; 4.4] 31.3 [17.6; 45.1] 2006 2003–2006: 7.6 [−1.8; 17.9]
2006–2014: 0.6 [−1.4; 2.6]
I 50.2 59.1 8.9 [5.9; 11.9] 17.7 [11.8; 23.7] 2008 2003–2008: 2.9 [2.2; 3.6]
2008–2014: 0.7 [0.2; 1.2]
II 54.1 71.7 17.5 [14.3; 20.8] 32.4 [26.5; 38.3] – 2003–2014: 2.8 [2.5; 3.2]
III 21.9 21.1 −0.8 [−2.7; 1.1] −3.6 [−12.3; 5.1] – 2003–2014: −0.3 [−0.9; 0.4]
IV 8.3 8.0 −0.2 [−1.5; 1.0] −2.9 [−17.9; 12.1] 2008
2012
2003–2008: −1.2 [−2.9; 0.5]
2008–2012: 3.2 [−1.2; 7.8]
2012–2014: −6.4 [−18.4; 7.3]
50–59 DCIS 15.7 40.3 24.6 [22.3; 26.9] 156.6 [141.8; 171.3] 2009 2003–2009: 20.4 [13.4; 27.7]
2009–2014: −1.4 [−8.9; 6.6]
I 90.7 119.1 28.4 [24.0; 32.8] 31.3 [26.5; 36.2] 2005
2009
2003–2005: −6.7 [−13.4; 0.5]
2005–2009: 12.5 [8.9; 16.3]
2009–2014: −2.4 [−3.7; −1.0]
II 89.0 90.2 1.2 [−2.8; 5.2] 1.4 [−3.1; 5.9] 2005
2008
2003–2005: −4.2 [−14.5; 7.3]
2005–2008: 6.5 [−4.9; 19.3]
2008–2014: −2.2 [−3.8; −0.5]
III 35.5 27.0 −8.6 [−10.9; −6.2] −24.2 [−30.8; −17.5] 2008 2003–2008: 0.9 [−1.7; 3.5]
2008–2014: −5.5 [−7.2; −3.7]
IV 16.6 12.8 −3.8 [−5.4; −2.2] −23.0 [−32.8; −13.2] 2008 2003–2008: 0.3 [−2.4; 3.1]
2008–2014: −4.8 [−6.8; −2.9]
60–69 DCIS 17.4 46.1 28.6 [26.2; 31.1] 164.1 [150.0; 178.2] 2005
2008
2003–2005: 4.3 [−26.7; 48.3]
2005–2008: 37.2 [−3.5; 95.1]
2008–2014: −1.9 [−7.6; 4.1]
I 118.5 171.9 53.5 [45.7; 61.2] 45.1 [38.6; 51.6] 2005
2008
2003–2005: −4.2 [−13.2; 5.6]
2005–2008: 22.1 [10.7; 34.6]
2008–2014: −2.8 [−4.5; −1.1]
II 111.9 109.7 −2.2 [−2.3; −2.1] −2.0 [−2.1; −1.8] 2005
2008
2003–2005: −1.5 [−19.3; 20.1]
2005–2008: 10.3 [−7.2; 31.0]
2008–2014: −5.6 [−7.4; −3.8]
III 47.5 34.1 −13.4 [−14.4; −12.5] −28.3 [−30.3; −26.3] 2008 2003–2008: 2.6 [−0.0; 5.3]
2008–2014: −8.0 [−9.7; −6.2]
IV 25.5 19.3 −6.1 [−6.8; −5.5] −24.2 [−26.6; −21.7] 2008 2003–2008: 1.8 [0.0; 3.5]
2008–2014: −6.5 [−7.6; −5.3]
70–79 DCIS 10.7 16.6 5.9 [4.1; 7.7] 54.7 [37.9; 71.5] 2007 2003–2007: 15.4 [9.4; 21.7]
2007–2014: −0.8−[−3.0; 1.5]
I 87.7 105.8 18.1 [13.3; 22.8] 20.6 [15.2; 26.0] – 2003–2014: 1.8 [1.4; 2.2]
II 115.6 127.0 11.4 [6.1; 16.8] 9.9 [5.3; 14.5] 2009 2003–2009: 2.3 [1.6; 3.0]
2009–2014: −0.4 [−1.3; 0.5]
III 53.7 51.7 −1.9 [−5.4; 1.6] −3.6 [−10.1; 2.9] 2007 2003–2007: 2.3 [−1.5; 6.2]
2007–2014: −2.2 [−3.6; −0.8]
IV 34.1 31.0 −3.1 [−5.8; −0.3] −9.0 [−17.0; −0.9] 2009 2003–2009: 0.4 [−0.5; 1.3]
(Continues)
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with baseline data. In both age groups joinpoint analysis
reveals an increase during the implementation phase of
screening (2005–2008), which is superseded by an ongoing
declining trend. Stage III and IV incidence only showed a
slight initial increase, marginal significant in the case of
Stage IV in the oldest age group, followed by a continuing
decrease since 2008, by −5.5%/−8.0% per year for Stage III
and −4.8%/−6.5% per year for Stage IV. The incidence in
2013/2014 was reduced by 24.2%/28.3% for Stage III and by
23.0%/24.2% for Stage IV compared to the prescreening
period. Trends in the age group of 70–79 years (22% of all
BC cases, Fig. 2e) and 80+ years (12% of all BC cases,
Fig. 2f ) showed increasing incidence for DCIS, Stage I and
II, but no typical, screening related prevalence peak. There
Table 2. Breast cancer incidence (rate/100,000) by age group (years) and stage (UICC): comparison of 2003/2004 (before introduction of
mammography screening (Mx) in 2005) with 2013/2014 (after introduction, most recent years) and results of trend analyses (joinpoint: year of













difference (%) Joinpoint Trend APC (%)
2009–2014: −2.5 [−3.7; −1.4]
80+ DCIS 4.4 5.8 1.4 [0.0; 2.7] 30.5 [−0.7; 61.6] 2007 2003–2007: 11.6 [−4.1; 30.0]
2007–2014: −2.6 [−8.6; 3.9]
I 50.8 54.6 3.8 [−0.5; 8.2] 7.6 [−1.0; 16.1] 2006
2010
2003–2006: 3.7 [−1.9; 9.6]
2006–2010: −1.9 [−6.9; 3.3]
2010–2014: 2.1 [−1.0; 5.3]
II 102.6 130.2 27.5 [21.0; 34.1] 26.8 [20.4; 33.2] 2005
2008
2003–2005: 9.0 [0.1; 18.8]
2005–2008: −0.5 [−8.1; 7.7]
2008–2014: 2.3 [1.4; 3.3]
III 60.8 60.4 −0.5 [−4.8; 3.9] −0.8 [−8.0; 6.5] 2005
2009
2003–2005: 9.3 [−4.8; 25.4]
2005–2009: −0.0 [−5.3; 5.6]
2009–2014: −3.1 [−5.3; −1.0]
IV 48.8 41.3 −7.5 [−11.6; −3.5] −15.5 [−23.8; −7.1] 2009 2003–2009: 0.2 [−1.6; 2.1]




Figure 3. Trends in breast cancer mortality in German regions (a) age-standardized rate (Europe) and (b) age-specific rates/100,000 women,
dots: observed rates, lines: modeled by joinpoint regression, vertical dotted line: year of implementation of mammography screening (2005).
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is a slightly declining trend for Stage III and IV, but mark-
edly smaller than in the screening age groups.
Mortality
A total of 281,284 women died from BC throughout the obser-
vation period from 1998 to 2016 in the study population. Age-
standardized BC mortality was 26.7/100,000 in the years before
the introduction of the mammography program (2003/2004)
and 23.2/100,000 in 2015/2016 (relative decrease: −12.9%,
Fig. 3a). Trend analyses revealed a decline of BC mortality in
almost all age groups until around the years 2008/2009, with
the highest decreases in the age groups up to 59 years (Table 3,
Fig. 3b). Then trends changed in all age groups. In both youn-
ger age groups (20–39 and 40–49 years) mortality remained
stable (APC: −0.8% and 0.2%, statistically not significant). In
the oldest age groups 70–79 and 80+ years trends reversed with
now significantly increasing mortality rates (APC: 0.7 and
2.9%). Only in the screening related age groups still an ongoing
significant decrease of BC mortality was observed in the latest
time period (APC: 50–59 years: −1.5%; 60–69 years: −3.3%).
Compared to the prescreening time period BC mortality in
these age groups was −25.8 and −21.2% lower in 2015/2016.
Discussion
The introduction of an organized, high-quality mammography
screening in Germany affected trends in breast cancer inci-
dence (total and stage-specific) and in BC mortality. The
results are based on a huge population with more than
320,000 BC cases and an underlying population of more than
15 million women, providing robust results for incidence and
mortality even in smaller subgroups.
Breast cancer incidence
As expected, our analysis shows an increase in BC incidence
in the screening age groups after the introduction of
mammography screening in Germany. The occurrence of a
typical prevalence peak, concurrent with full implementation
in 2009 and is restricted to screening exposed age groups pro-
vides evidence for a causal relationship with the screening
intervention. Similar prevalence peaks were also observed in
other countries after the introduction of organized mammog-
raphy screening programs.8–11 While the incidence of invasive
BC almost fell to the level of the prescreening period about
10 years after the start of the screening program, incidence of
DCIS remained substantially elevated since the year of full
implementation of the screening (2009). In the long term, an
excess of total incidence (in situ and invasive carcinomas)
after introducing screening might indicate overdiagnosis, that
is, cancer cases that would not have been diagnosed in the
absence of screening and which represent a much-noticed
adverse consequence of mammography screening. Based on a
period of 10 years after the start of BC screening program and
assuming no underlying secular incidence trends, our results
suggest a screening-related excess in total BC incidence of
17–19% in the screening age groups, reflecting a moderate
fraction of overdiagnosed BCs. This result is in the range
reported from randomized controlled trials or cohort studies
(10–22% and 1–36.2%, respectively).12
Stage-specific breast cancer incidence
The reduction of advanced BC incidence could be considered
as an early surrogate marker for a later reduction of disease-
specific mortality.13,14 Prognosis of breast cancer depends
strongly on the stage of disease at presentation, with signifi-
cantly lower survival for advanced stages.15,16 If a BC screen-
ing is effective in reducing the incidence of advanced cancers,
by detecting BC before an unfavorable, late-stage is developed,
a decline of disease-specific mortality may be expected to fol-
low over the next years. Although one might argue that the
decrease in incidence of late-stage cancers is a necessary, but
Table 3. Breast cancer mortality (age-specific rate/100,000) by age group (years): comparison of 2003/2004 (before introduction of
mammography screening in 2005) with 2015/2016 and results of trend analyses 1998–2016 (joinpoint: year of change in trend, trend as







100,000 Difference % Joinpoint Trend APC (%)
20–39 3.2 2.4 −0.8 [−1.1; −0.4] −23.8 [−34.9; −12.6] 2008 1998–2008: −4.3 [−5.5; −3.2]
2008–2016: −0.8 [−2.5; 1.0]
40–49 20.2 17.0 −3.3 [−4.4; −2.1] −16.1 [−22.0; −10.2] 2008 1998–2008: −4.0 [−4.6; −3.5]
2008–2016: −0.2 [−0.6; 1.0]
50–59 48.9 36.3 −12.6 [−14.5; −10.8] −25.8 [−29.6; −22.0] 2010 1998–2010: −3.4 [−3.9; −3.0]
2010–2016: −1.5 [−2.9; −0.0]
60–69 79.9 62.9 −16.9 [−19.4; −14.4] −21.2 [−24.3; −18.0] 2009 1998–2009: –0.1 [−0.6; 0.5]
2008–2016: −3.3 [−4.2; −2.3]
70–79 111.6 114.3 2.8 [−0.8; 6.3] −2.5 [−0.7; −5.6] 2008 1998–2008: −1.0 [−1.5; −0.5]
2008–2016: 0.7 [0.1; 1.4]
80+ 187.5 213.6 26.1 [20.3; 31.9] 13.9 [10.9; 17.0] 2007 1998–2007: −1.5 [−2.0; −1.0]
2007–2016: 2.0 [1.4; 2.5]
12003/2004.
22015/2016.
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not sufficient, condition for a screening program to reduce
mortality,17 there is evidence of a causal relationship between
these parameters in the case of BC. Based on an analysis of
eight RCTs on mammography screening, it has been shown
that reductions in the incidence of advanced BC were directly
proportional to mortality reductions.18
In our study, a continuing decline in advanced BC inci-
dence was observed in the screening related age groups (50–-
69 years). Ten years after the first implementation of the
screening program Stage III and IV BC dropped significantly
by about a quarter (50–59 years: III: −24.2%, IV: −23.0%;
60–69 years: III: −28.3%, IV: −24.2%). No or substantially
smaller changes were seen in the not exposed age groups
(20–49 and 80+ years). Opposing effects were observed for
early cancer stages with a marked increase in the screening
age groups (DCIS: 156.6%, 164.1%; I: 31.3%, 45.1%), while the
nonexposed groups showed only minor increases. Especially
the increase in DCIS proofs that the introduced mammogra-
phy screening was effective in terms of detecting small breast
cancers, because DCIS is rarely discovered by symptoms.19,20
All in all, declining advanced stage and increasing early-stage
BC incidence in the screening age groups, but not in the
others as shown in Figure 2, paint a consistent picture of the
expected effects on stage-specific incidence after the introduc-
tion of an effective screening program.
One limitation in the interpretation of our result is whether
the observed decline of advanced stages can be attributed to the
implementation of the mammography screening. In general,
incidence trends are not only influenced by screening use, but
typically affected by changes in the prevalence of risk factors
(e.g., reproductive behavior, use of hormone replacement ther-
apy or obesity). A priori, it cannot be ruled out, that changes in
some risks might be age-related. Hypothesizing such changes,
however, they should have similar effects on all stages and are
therefore incapable to explain isolated effects on late-stage
BC. Reversely, changes in stage distribution, as they might
result from improved diagnostic techniques (e.g., increased use
of sentinel lymph node biopsy) should be observable in all age
groups; furthermore, they should rather lead to an increase of
advanced BC than to a decline.21 However, we have no indica-
tion that factors mentioned above had substantial impact an
BC incidence in the investigated time period. In our case, the
decline of advanced BC was isolated to the screening exposed
age group making other factors improbable. Therefore, we con-
clude that even if the evidence level of our observation is lim-
ited, a causal relationship between the implementation of the
mammography screening program in Germany and the
observed stage-specific trends seems likely. A precise estimate
of the extent to which screening reduces the incidence of late-
stage BC, is not possible due to the observational nature of our
data. However, there is good reason to believe that this capacity
is stronger than our comparative analysis suggests. To control
for incidence trends in the absence of screening we considered
BC incidence before the implementation of the screening
program and corresponding trends in nonexposed age groups.
Both references, however, are obviously contaminated by
opportunistic screening activities. Especially in the screening
related age groups, incidences of DCIS at baseline is already
high, indicating substantial opportunistic screening use before
the start of the program. But also in the adjacent age groups
(40–49 years and 70–79 years) incidence of DCIS provides evi-
dence that screening activities took place in 2003/2004 and in
the following years. Because of this, our comparisons target also
the population effect of quantitative and qualitative improve-
ments in early detection of BC rather than only the effects of
screening versus no screening. The resulting difficulties with
respect to the evaluation of the program had been foreseen
already before the start of the program.20 Our results may be
limited by the exclusion of DCO cases, in which a higher pro-
portion of late-stage cancers is likely. Sensitivity analyses, which
replaced DCO cases by late-stage cancer, showed even stronger
declines for advanced stage incidence (due to declining DCO
rate over time). In this respect, our results seem to be rather
conservative.
A reduction of advanced stages in BC has been found in
several studies on mammography screening programs in other
regions.17,22,23 Some studies, however, did not find such an
effect or found only transient drops.24,25 A consistent pattern
of factors that explain the variance of such study results has
not become apparent so far. Methodological differences
include the length of the observation period, the definition of
advanced BC (UICC or tumor size) and the definition of the
age groups compared. These differences often hamper the
comparability of publications on stage-specific incidence. An
analysis of the Dutch mammography screening, for example,
found little impact on the burden of advanced BC. Unlike our
approach, all BCs of Stage II and higher had been categorized
as advanced BCs.26 Thus, benefits of screening which result
from a shift to lower stages within this spectrum are over-
looked. Further dilution of possible effects arises from the
choice to assign all women at the age of 50 years or older to
the exposed age group, although only women until the age of
69, later expanded to 74 were invited for screening. Less favor-
able results of other studies may also arise from different
background incidence trends. An investigation of late-stage
BC incidence before and after the introduction of mammogra-
phy screening in the United States, for example, found only a
small decrease by 8% over an observation period of three
decades.11 However, the conclusion that screening reduced the
incidence of advanced BC only marginally, critically depends
on the assumption of a constant underlying disease burden.
This condition is questionable. Early incidence trends in the
screening age group (1976–1985) show a clear increase of
late-stage BC. With the introduction of mammography
screening this trend was stopped. Without screening it could
be assumed that late-stage BC would have increased further
on. Therefore, the reported decrease of 8% in our study might
be a rather relevant effect.
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Even if there is no totally clear picture of declining late-
stage BC incidence after introduction of mammography
screening in the literature, our result, which are based on a
strict stratification of screening exposure and exact stage, sup-
pose a beneficial effect of mammography screening on late-
stage BC incidence.
Breast cancer mortality
The ultimate goal of mammography screening is a reduction
of BC mortality. The proof of this effect on the population
level is a big challenge because trends in mortality are
influenced not only by changes in the disease but also by
improvements in treatment. In Germany, a constant decline
in BC mortality was already seen in all age groups before the
introduction of the mammography screening in 2005. This
trend might reflect the ongoing advances in BC therapy.
When an effective BC screening is introduced, one would
expect that the decline in BC mortality would be strengthened,
mainly in the screening age group. Interestingly the declining
trend in BC mortality stopped around the year 2008/2009 in
the nonexposed age groups, whereas even a significant
increase was observed for patients aged 70 and older. Only in
the screening exposed age groups still favorable trends are
present with an annual percentage decline of −1.5% (50–
59 years, starting 2010) and −3.3% (60–69 years, starting
2009). Both screening age groups also show the largest abso-
lute reduction in BC mortality. This is in line with results
from RCTs that suggest effects on mortality to appear at about
4 years after the first screenings and to fully emerge after
about 10 years.27 Other population-based studies also found a
close temporal connection between the implementation of a
mammography screening and trend changes in mortality.28–31
We have to take into account the possibility that effects on
mortality were accelerated by an increase of breast cancer
awareness and opportunistic screening in the run-up to the
program.
Summarizing the results, we conclude that the observed
trend changes in BC mortality, with continuing decline in the
screening exposed group and not in the nonexposed groups,
fit very well to expected effects of an effective mammography
screening. It remains unclear to what extent the screening
contributed to the reduction in BC mortality. Further analyses
are needed here.
Attendance rate
The attendance rate to the German mammography screening
is about 50%. Compared to other European programs, achiev-
ing attendance rates of 70% and more,29,32,33 screening uptake
in the official German program seems to be relatively low.
The question arises as to whether the observed results in our
study are consistent with this moderate participation rate.
Would the effects, mortality decline as well as the proportion
of overdiagnosis, intensify if participation in the program
increased? This seems to be unlikely. Unfortunately, the
German health care system opens different ways of getting
screening mammography outside the official screening pro-
gram (opportunistic screening). The results of a recent survey
showed that 73% of women in the screening age group had a
mammography in the last 2 years (83% for “ever” had a mam-
mogram)34 which is in compliance with earlier surveys.35,36
Insofar a realistic screening rate for Germany might be clearly
higher than 50%, likely about 70% and comparable to other
European countries. Such an attendance rate could explain the
extent of the observed population-based effects on late-stage
BC, overdiagnosis and mortality as well.
Limitations
A limitation of our study results from its relatively short
observation period, but more recent data is not available. The
lack of long-term data on incidence before the screening pro-
gram impedes a more in-depth consideration of background
trends beyond comparison of different age groups alone.
Availability of more recent data, on the other hand, might
reveal delayed effects, particularly with respect to disease-
specific mortality.
Conclusions
The observed reduction of late-stage breast cancer incidence
in the screening exposed age group in Germany is most likely
to be attributed to the introduction of the national mammog-
raphy screening program. In addition, the observed reduction
of disease-specific mortality fits the expected pattern, but the
proportion to which the mammography screening contributed
to the reduction is unclear. These positive effects are bought
at the cost of a moderate occurrence of overdiagnosis, espe-
cially by a sharp increase of in situ cancers.
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